2012;60: 1249 56. 36. Wang TJ, Wollert KC, Larson MG, et al. Prognostic utility of novel bio- markers of cardiovascular stress: the Framingham Heart Study. Circulation. 2012;126:1596 604. 37. Xanthakis V, Larson MG, Wollert KC, et al. Association of novel biomark- ers of cardiovascular stress with left ventricular hypertrophy and dysfunc- tion: implications for screening. J Am Heart Assoc. 2013;2:e000399. 38. Anwaruddin S, Lloyd-Jones DM, Baggish A, et al. Renal function, con- gestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol. 2006;47:91 7. 39. Redfield MM, Rodeheffer RJ, Jacobsen SJ, et al. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol. 2002;40:976 82. 40. Wang TJ, Larson MG, Levy D, et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol. 2002;90:254 8. Yancy et al 41. Chang AY, Abdullah SM, Jain T, et al. Associations among androgens, estrogens, and natriuretic peptides in young women: observations from the Dallas Heart Study. J Am Coll Cardiol. 2007;49:109 16. 42. Clerico A, Giannoni A, Vittorini S, et al. The paradox of low BNP levels in obesity. Heart Fail Rev. 2012;17:81 96. 43. De Vecchis R, Esposito C, Di Biase G, et al. B-type natriuretic peptide- guided versus symptom-guided therapy in outpatients with chronic heart failure: a systematic review with meta-analysis. J Cardiovasc Med (Hager- stown). 2014;15:122 34. 44. Felker GM, Hasselblad V, Hernandez AF, et al. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J. 2009;158:422 30. 45. Li P, Luo Y, Chen YM. B-type natriuretic peptide-guided chronic heart failure therapy: a meta-analysis of 11 randomised controlled trials. Heart Lung Circ. 2013;22:852 60. 46. 